CNS5:Oligodendroglioma, IDH-mutant and 1p/19q-codeleted - Revision history

Bailey.Glen at 17:39, 3 July 2025

2025-07-03T17:39:41Z

← Older revision		Revision as of 12:39, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 22:00, 25 May 2025

2025-05-25T22:00:04Z

← Older revision		Revision as of 17:00, 25 May 2025
Line 150:		Line 150:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 231:		Line 231:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 286:		Line 286:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 335:		Line 335:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:45, 25 May 2025

2025-05-25T20:45:04Z

← Older revision		Revision as of 15:45, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted
	\|}		\|}

Bailey.Glen at 19:44, 25 May 2025

2025-05-25T19:44:14Z

← Older revision		Revision as of 14:44, 25 May 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Oligodendroglioma, IDH-mutant and 1p/19q-codeleted}}		{{DISPLAYTITLE:Oligodendroglioma, IDH-mutant and 1p/19q-codeleted}}

	[[CNS5:Table_of_Contents\|Central Nervous System Tumours(WHO Classification, 5th ed.)]]		[[CNS5:Table_of_Contents\|Central Nervous System Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

Jennelleh at 01:31, 28 March 2025

2025-03-28T01:31:24Z

@@ Line 11: / Line 11: @@
 Shashirekha Shetty, PhD, Director, Cytogenetics Laboratory, Center for Human Genetics Laboratory, University Hospitals
 ==WHO Classification of Disease==
@@ Line 33: / Line 32: @@
 |Subtype(s)
 |Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
 |}

Jennelleh at 20:23, 27 March 2025

2025-03-27T20:23:27Z

← Older revision		Revision as of 15:23, 27 March 2025
Line 98:		Line 98:


			'''Add content below into table above'''
	- Oligodendrogliomas are defined by a t(1;19)(q10;p10) rearrangement that results in 1p/19q whole-arm codeletion		- Oligodendrogliomas are defined by a t(1;19)(q10;p10) rearrangement that results in 1p/19q whole-arm codeletion

Line 178:		Line 178:


			'''Add content below into table above'''
	Put your text here and fill in the table		Put your text here and fill in the table

Line 239:		Line 239:


			'''Add content below into table above'''
	Put your text here		Put your text here

Line 306:		Line 306:


			'''Add content below into table above'''
	Put your text here and fill in the table		Put your text here and fill in the table

Line 397:		Line 397:
	\|}		\|}
	Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.		Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 501:		Line 500:
	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

	* Positive (universal) - Retained nuclear ATRX<ref name=":5">{{Cite journal\|last=Liu\|first=Xiao-Yang\|last2=Gerges\|first2=Noha\|last3=Korshunov\|first3=Andrey\|last4=Sabha\|first4=Nesrin\|last5=Khuong-Quang\|first5=Dong-Anh\|last6=Fontebasso\|first6=Adam M.\|last7=Fleming\|first7=Adam\|last8=Hadjadj\|first8=Djihad\|last9=Schwartzentruber\|first9=Jeremy\|date=2012-11\|title=Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations\|url=https://pubmed.ncbi.nlm.nih.gov/22886134\|journal=Acta Neuropathologica\|volume=124\|issue=5\|pages=615–625\|doi=10.1007/s00401-012-1031-3\|issn=1432-0533\|pmid=22886134}}</ref>, OLIG2<ref name=":21">{{Cite journal\|last=Ligon\|first=Keith L.\|last2=Alberta\|first2=John A.\|last3=Kho\|first3=Alvin T.\|last4=Weiss\|first4=Jennifer\|last5=Kwaan\|first5=Mary R.\|last6=Nutt\|first6=Catherine L.\|last7=Louis\|first7=David N.\|last8=Stiles\|first8=Charles D.\|last9=Rowitch\|first9=David H.\|date=2004-05\|title=The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/15198128\|journal=Journal of Neuropathology and Experimental Neurology\|volume=63\|issue=5\|pages=499–509\|doi=10.1093/jnen/63.5.499\|issn=0022-3069\|pmid=15198128}}</ref>, S100<ref name=":22">{{Cite journal\|last=Reifenberger\|first=G.\|last2=Szymas\|first2=J.\|last3=Wechsler\|first3=W.\|date=1987\|title=Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system\|url=https://pubmed.ncbi.nlm.nih.gov/3314309\|journal=Acta Neuropathologica\|volume=74\|issue=2\|pages=105–123\|doi=10.1007/BF00692841\|issn=0001-6322\|pmid=3314309}}</ref>, MAP2<ref name=":23">{{Cite journal\|last=Blümcke\|first=I.\|last2=Becker\|first2=A. J.\|last3=Normann\|first3=S.\|last4=Hans\|first4=V.\|last5=Riederer\|first5=B. M.\|last6=Krajewski\|first6=S.\|last7=Wiestler\|first7=O. D.\|last8=Reifenberger\|first8=G.\|date=2001-10\|title=Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells\|url=https://pubmed.ncbi.nlm.nih.gov/11589429\|journal=Journal of Neuropathology and Experimental Neurology\|volume=60\|issue=10\|pages=984–993\|doi=10.1093/jnen/60.10.984\|issn=0022-3069\|pmid=11589429}}</ref>, SOX10<ref name=":24">{{Cite journal\|last=Bannykh\|first=Sergei I.\|last2=Stolt\|first2=C. Claus\|last3=Kim\|first3=Jung\|last4=Perry\|first4=Arie\|last5=Wegner\|first5=Michael\|date=2006-01\|title=Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/16205963\|journal=Journal of Neuro-Oncology\|volume=76\|issue=2\|pages=115–127\|doi=10.1007/s11060-005-5533-x\|issn=0167-594X\|pmid=16205963}}</ref>		*Positive (universal) - Retained nuclear ATRX<ref name=":5">{{Cite journal\|last=Liu\|first=Xiao-Yang\|last2=Gerges\|first2=Noha\|last3=Korshunov\|first3=Andrey\|last4=Sabha\|first4=Nesrin\|last5=Khuong-Quang\|first5=Dong-Anh\|last6=Fontebasso\|first6=Adam M.\|last7=Fleming\|first7=Adam\|last8=Hadjadj\|first8=Djihad\|last9=Schwartzentruber\|first9=Jeremy\|date=2012-11\|title=Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations\|url=https://pubmed.ncbi.nlm.nih.gov/22886134\|journal=Acta Neuropathologica\|volume=124\|issue=5\|pages=615–625\|doi=10.1007/s00401-012-1031-3\|issn=1432-0533\|pmid=22886134}}</ref>, OLIG2<ref name=":21">{{Cite journal\|last=Ligon\|first=Keith L.\|last2=Alberta\|first2=John A.\|last3=Kho\|first3=Alvin T.\|last4=Weiss\|first4=Jennifer\|last5=Kwaan\|first5=Mary R.\|last6=Nutt\|first6=Catherine L.\|last7=Louis\|first7=David N.\|last8=Stiles\|first8=Charles D.\|last9=Rowitch\|first9=David H.\|date=2004-05\|title=The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/15198128\|journal=Journal of Neuropathology and Experimental Neurology\|volume=63\|issue=5\|pages=499–509\|doi=10.1093/jnen/63.5.499\|issn=0022-3069\|pmid=15198128}}</ref>, S100<ref name=":22">{{Cite journal\|last=Reifenberger\|first=G.\|last2=Szymas\|first2=J.\|last3=Wechsler\|first3=W.\|date=1987\|title=Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system\|url=https://pubmed.ncbi.nlm.nih.gov/3314309\|journal=Acta Neuropathologica\|volume=74\|issue=2\|pages=105–123\|doi=10.1007/BF00692841\|issn=0001-6322\|pmid=3314309}}</ref>, MAP2<ref name=":23">{{Cite journal\|last=Blümcke\|first=I.\|last2=Becker\|first2=A. J.\|last3=Normann\|first3=S.\|last4=Hans\|first4=V.\|last5=Riederer\|first5=B. M.\|last6=Krajewski\|first6=S.\|last7=Wiestler\|first7=O. D.\|last8=Reifenberger\|first8=G.\|date=2001-10\|title=Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells\|url=https://pubmed.ncbi.nlm.nih.gov/11589429\|journal=Journal of Neuropathology and Experimental Neurology\|volume=60\|issue=10\|pages=984–993\|doi=10.1093/jnen/60.10.984\|issn=0022-3069\|pmid=11589429}}</ref>, SOX10<ref name=":24">{{Cite journal\|last=Bannykh\|first=Sergei I.\|last2=Stolt\|first2=C. Claus\|last3=Kim\|first3=Jung\|last4=Perry\|first4=Arie\|last5=Wegner\|first5=Michael\|date=2006-01\|title=Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/16205963\|journal=Journal of Neuro-Oncology\|volume=76\|issue=2\|pages=115–127\|doi=10.1007/s11060-005-5533-x\|issn=0167-594X\|pmid=16205963}}</ref>
	* Positive (subset) - Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref name=":25">{{Cite journal\|last=Capper\|first=David\|last2=Zentgraf\|first2=Hanswalter\|last3=Balss\|first3=Jörg\|last4=Hartmann\|first4=Christian\|last5=von Deimling\|first5=Andreas\|date=2009-11\|title=Monoclonal antibody specific for IDH1 R132H mutation\|url=https://pubmed.ncbi.nlm.nih.gov/19798509\|journal=Acta Neuropathologica\|volume=118\|issue=5\|pages=599–601\|doi=10.1007/s00401-009-0595-z\|issn=1432-0533\|pmid=19798509}}</ref>, Synaptophysin (cytoplasmic dot-like pattern<ref name=":26">{{Cite journal\|last=Perry\|first=Arie\|last2=Burton\|first2=Stephanie S.\|last3=Fuller\|first3=Gregory N.\|last4=Robinson\|first4=Christopher A.\|last5=Palmer\|first5=Cheryl A.\|last6=Resch\|first6=Lothar\|last7=Bigio\|first7=Eileen H.\|last8=Gujrati\|first8=Meena\|last9=Rosenblum\|first9=Marc K.\|date=2010-08\|title=Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall\|url=https://pubmed.ncbi.nlm.nih.gov/20464403\|journal=Acta Neuropathologica\|volume=120\|issue=2\|pages=237–252\|doi=10.1007/s00401-010-0695-9\|issn=1432-0533\|pmc=2892612\|pmid=20464403}}</ref>)		*Positive (subset) - Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref name=":25">{{Cite journal\|last=Capper\|first=David\|last2=Zentgraf\|first2=Hanswalter\|last3=Balss\|first3=Jörg\|last4=Hartmann\|first4=Christian\|last5=von Deimling\|first5=Andreas\|date=2009-11\|title=Monoclonal antibody specific for IDH1 R132H mutation\|url=https://pubmed.ncbi.nlm.nih.gov/19798509\|journal=Acta Neuropathologica\|volume=118\|issue=5\|pages=599–601\|doi=10.1007/s00401-009-0595-z\|issn=1432-0533\|pmid=19798509}}</ref>, Synaptophysin (cytoplasmic dot-like pattern<ref name=":26">{{Cite journal\|last=Perry\|first=Arie\|last2=Burton\|first2=Stephanie S.\|last3=Fuller\|first3=Gregory N.\|last4=Robinson\|first4=Christopher A.\|last5=Palmer\|first5=Cheryl A.\|last6=Resch\|first6=Lothar\|last7=Bigio\|first7=Eileen H.\|last8=Gujrati\|first8=Meena\|last9=Rosenblum\|first9=Marc K.\|date=2010-08\|title=Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall\|url=https://pubmed.ncbi.nlm.nih.gov/20464403\|journal=Acta Neuropathologica\|volume=120\|issue=2\|pages=237–252\|doi=10.1007/s00401-010-0695-9\|issn=1432-0533\|pmc=2892612\|pmid=20464403}}</ref>)
	* Negative (universal) - Lack diffuse p53<ref name=":5" />		*Negative (universal) - Lack diffuse p53<ref name=":5" />
	* Negative (subset) - N/A		*Negative (subset) - N/A

	==Links==		==Links==

Jennelleh at 20:20, 27 March 2025

2025-03-27T20:20:38Z

← Older revision		Revision as of 15:20, 27 March 2025
Line 501:		Line 501:
	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

	Positive (universal) - Retained nuclear ATRX<ref name=":5">{{Cite journal\|last=Liu\|first=Xiao-Yang\|last2=Gerges\|first2=Noha\|last3=Korshunov\|first3=Andrey\|last4=Sabha\|first4=Nesrin\|last5=Khuong-Quang\|first5=Dong-Anh\|last6=Fontebasso\|first6=Adam M.\|last7=Fleming\|first7=Adam\|last8=Hadjadj\|first8=Djihad\|last9=Schwartzentruber\|first9=Jeremy\|date=2012-11\|title=Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations\|url=https://pubmed.ncbi.nlm.nih.gov/22886134\|journal=Acta Neuropathologica\|volume=124\|issue=5\|pages=615–625\|doi=10.1007/s00401-012-1031-3\|issn=1432-0533\|pmid=22886134}}</ref>, OLIG2<ref name=":21">{{Cite journal\|last=Ligon\|first=Keith L.\|last2=Alberta\|first2=John A.\|last3=Kho\|first3=Alvin T.\|last4=Weiss\|first4=Jennifer\|last5=Kwaan\|first5=Mary R.\|last6=Nutt\|first6=Catherine L.\|last7=Louis\|first7=David N.\|last8=Stiles\|first8=Charles D.\|last9=Rowitch\|first9=David H.\|date=2004-05\|title=The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/15198128\|journal=Journal of Neuropathology and Experimental Neurology\|volume=63\|issue=5\|pages=499–509\|doi=10.1093/jnen/63.5.499\|issn=0022-3069\|pmid=15198128}}</ref>, S100<ref name=":22">{{Cite journal\|last=Reifenberger\|first=G.\|last2=Szymas\|first2=J.\|last3=Wechsler\|first3=W.\|date=1987\|title=Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system\|url=https://pubmed.ncbi.nlm.nih.gov/3314309\|journal=Acta Neuropathologica\|volume=74\|issue=2\|pages=105–123\|doi=10.1007/BF00692841\|issn=0001-6322\|pmid=3314309}}</ref>, MAP2<ref name=":23">{{Cite journal\|last=Blümcke\|first=I.\|last2=Becker\|first2=A. J.\|last3=Normann\|first3=S.\|last4=Hans\|first4=V.\|last5=Riederer\|first5=B. M.\|last6=Krajewski\|first6=S.\|last7=Wiestler\|first7=O. D.\|last8=Reifenberger\|first8=G.\|date=2001-10\|title=Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells\|url=https://pubmed.ncbi.nlm.nih.gov/11589429\|journal=Journal of Neuropathology and Experimental Neurology\|volume=60\|issue=10\|pages=984–993\|doi=10.1093/jnen/60.10.984\|issn=0022-3069\|pmid=11589429}}</ref>, SOX10<ref name=":24">{{Cite journal\|last=Bannykh\|first=Sergei I.\|last2=Stolt\|first2=C. Claus\|last3=Kim\|first3=Jung\|last4=Perry\|first4=Arie\|last5=Wegner\|first5=Michael\|date=2006-01\|title=Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/16205963\|journal=Journal of Neuro-Oncology\|volume=76\|issue=2\|pages=115–127\|doi=10.1007/s11060-005-5533-x\|issn=0167-594X\|pmid=16205963}}</ref>		* Positive (universal) - Retained nuclear ATRX<ref name=":5">{{Cite journal\|last=Liu\|first=Xiao-Yang\|last2=Gerges\|first2=Noha\|last3=Korshunov\|first3=Andrey\|last4=Sabha\|first4=Nesrin\|last5=Khuong-Quang\|first5=Dong-Anh\|last6=Fontebasso\|first6=Adam M.\|last7=Fleming\|first7=Adam\|last8=Hadjadj\|first8=Djihad\|last9=Schwartzentruber\|first9=Jeremy\|date=2012-11\|title=Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations\|url=https://pubmed.ncbi.nlm.nih.gov/22886134\|journal=Acta Neuropathologica\|volume=124\|issue=5\|pages=615–625\|doi=10.1007/s00401-012-1031-3\|issn=1432-0533\|pmid=22886134}}</ref>, OLIG2<ref name=":21">{{Cite journal\|last=Ligon\|first=Keith L.\|last2=Alberta\|first2=John A.\|last3=Kho\|first3=Alvin T.\|last4=Weiss\|first4=Jennifer\|last5=Kwaan\|first5=Mary R.\|last6=Nutt\|first6=Catherine L.\|last7=Louis\|first7=David N.\|last8=Stiles\|first8=Charles D.\|last9=Rowitch\|first9=David H.\|date=2004-05\|title=The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/15198128\|journal=Journal of Neuropathology and Experimental Neurology\|volume=63\|issue=5\|pages=499–509\|doi=10.1093/jnen/63.5.499\|issn=0022-3069\|pmid=15198128}}</ref>, S100<ref name=":22">{{Cite journal\|last=Reifenberger\|first=G.\|last2=Szymas\|first2=J.\|last3=Wechsler\|first3=W.\|date=1987\|title=Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system\|url=https://pubmed.ncbi.nlm.nih.gov/3314309\|journal=Acta Neuropathologica\|volume=74\|issue=2\|pages=105–123\|doi=10.1007/BF00692841\|issn=0001-6322\|pmid=3314309}}</ref>, MAP2<ref name=":23">{{Cite journal\|last=Blümcke\|first=I.\|last2=Becker\|first2=A. J.\|last3=Normann\|first3=S.\|last4=Hans\|first4=V.\|last5=Riederer\|first5=B. M.\|last6=Krajewski\|first6=S.\|last7=Wiestler\|first7=O. D.\|last8=Reifenberger\|first8=G.\|date=2001-10\|title=Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells\|url=https://pubmed.ncbi.nlm.nih.gov/11589429\|journal=Journal of Neuropathology and Experimental Neurology\|volume=60\|issue=10\|pages=984–993\|doi=10.1093/jnen/60.10.984\|issn=0022-3069\|pmid=11589429}}</ref>, SOX10<ref name=":24">{{Cite journal\|last=Bannykh\|first=Sergei I.\|last2=Stolt\|first2=C. Claus\|last3=Kim\|first3=Jung\|last4=Perry\|first4=Arie\|last5=Wegner\|first5=Michael\|date=2006-01\|title=Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/16205963\|journal=Journal of Neuro-Oncology\|volume=76\|issue=2\|pages=115–127\|doi=10.1007/s11060-005-5533-x\|issn=0167-594X\|pmid=16205963}}</ref>
			* Positive (subset) - Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref name=":25">{{Cite journal\|last=Capper\|first=David\|last2=Zentgraf\|first2=Hanswalter\|last3=Balss\|first3=Jörg\|last4=Hartmann\|first4=Christian\|last5=von Deimling\|first5=Andreas\|date=2009-11\|title=Monoclonal antibody specific for IDH1 R132H mutation\|url=https://pubmed.ncbi.nlm.nih.gov/19798509\|journal=Acta Neuropathologica\|volume=118\|issue=5\|pages=599–601\|doi=10.1007/s00401-009-0595-z\|issn=1432-0533\|pmid=19798509}}</ref>, Synaptophysin (cytoplasmic dot-like pattern<ref name=":26">{{Cite journal\|last=Perry\|first=Arie\|last2=Burton\|first2=Stephanie S.\|last3=Fuller\|first3=Gregory N.\|last4=Robinson\|first4=Christopher A.\|last5=Palmer\|first5=Cheryl A.\|last6=Resch\|first6=Lothar\|last7=Bigio\|first7=Eileen H.\|last8=Gujrati\|first8=Meena\|last9=Rosenblum\|first9=Marc K.\|date=2010-08\|title=Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall\|url=https://pubmed.ncbi.nlm.nih.gov/20464403\|journal=Acta Neuropathologica\|volume=120\|issue=2\|pages=237–252\|doi=10.1007/s00401-010-0695-9\|issn=1432-0533\|pmc=2892612\|pmid=20464403}}</ref>)
	Positive (subset) - Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref name=":25">{{Cite journal\|last=Capper\|first=David\|last2=Zentgraf\|first2=Hanswalter\|last3=Balss\|first3=Jörg\|last4=Hartmann\|first4=Christian\|last5=von Deimling\|first5=Andreas\|date=2009-11\|title=Monoclonal antibody specific for IDH1 R132H mutation\|url=https://pubmed.ncbi.nlm.nih.gov/19798509\|journal=Acta Neuropathologica\|volume=118\|issue=5\|pages=599–601\|doi=10.1007/s00401-009-0595-z\|issn=1432-0533\|pmid=19798509}}</ref>, Synaptophysin (cytoplasmic dot-like pattern<ref name=":26">{{Cite journal\|last=Perry\|first=Arie\|last2=Burton\|first2=Stephanie S.\|last3=Fuller\|first3=Gregory N.\|last4=Robinson\|first4=Christopher A.\|last5=Palmer\|first5=Cheryl A.\|last6=Resch\|first6=Lothar\|last7=Bigio\|first7=Eileen H.\|last8=Gujrati\|first8=Meena\|last9=Rosenblum\|first9=Marc K.\|date=2010-08\|title=Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall\|url=https://pubmed.ncbi.nlm.nih.gov/20464403\|journal=Acta Neuropathologica\|volume=120\|issue=2\|pages=237–252\|doi=10.1007/s00401-010-0695-9\|issn=1432-0533\|pmc=2892612\|pmid=20464403}}</ref>)		* Negative (universal) - Lack diffuse p53<ref name=":5" />
			* Negative (subset) - N/A
	Negative (universal) - Lack diffuse p53<ref name=":5" />

	Negative (subset) - N/A

	==Links==		==Links==

Jennelleh at 20:19, 27 March 2025

2025-03-27T20:19:53Z

Show changes

Jennelleh at 20:19, 27 March 2025

2025-03-27T20:19:12Z

Jennelleh at 20:17, 27 March 2025

2025-03-27T20:17:13Z

← Older revision		Revision as of 15:17, 27 March 2025
Line 134:		Line 134:
	!Finding!!Marker		!Finding!!Marker
	\|-		\|-
	\|Positive (universal)\|\|Retained nuclear ATRX<ref name=":5">{{Cite journal\|last=Liu\|first=Xiao-Yang\|last2=Gerges\|first2=Noha\|last3=Korshunov\|first3=Andrey\|last4=Sabha\|first4=Nesrin\|last5=Khuong-Quang\|first5=Dong-Anh\|last6=Fontebasso\|first6=Adam M.\|last7=Fleming\|first7=Adam\|last8=Hadjadj\|first8=Djihad\|last9=Schwartzentruber\|first9=Jeremy\|date=2012-11\|title=Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations\|url=https://pubmed.ncbi.nlm.nih.gov/22886134\|journal=Acta Neuropathologica\|volume=124\|issue=5\|pages=615–625\|doi=10.1007/s00401-012-1031-3\|issn=1432-0533\|pmid=22886134}}</ref>, OLIG2<ref>{{Cite journal\|last=Ligon\|first=Keith L.\|last2=Alberta\|first2=John A.\|last3=Kho\|first3=Alvin T.\|last4=Weiss\|first4=Jennifer\|last5=Kwaan\|first5=Mary R.\|last6=Nutt\|first6=Catherine L.\|last7=Louis\|first7=David N.\|last8=Stiles\|first8=Charles D.\|last9=Rowitch\|first9=David H.\|date=2004-05\|title=The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/15198128\|journal=Journal of Neuropathology and Experimental Neurology\|volume=63\|issue=5\|pages=499–509\|doi=10.1093/jnen/63.5.499\|issn=0022-3069\|pmid=15198128}}</ref>, S100<ref>{{Cite journal\|last=Reifenberger\|first=G.\|last2=Szymas\|first2=J.\|last3=Wechsler\|first3=W.\|date=1987\|title=Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system\|url=https://pubmed.ncbi.nlm.nih.gov/3314309\|journal=Acta Neuropathologica\|volume=74\|issue=2\|pages=105–123\|doi=10.1007/BF00692841\|issn=0001-6322\|pmid=3314309}}</ref>, MAP2<ref>{{Cite journal\|last=Blümcke\|first=I.\|last2=Becker\|first2=A. J.\|last3=Normann\|first3=S.\|last4=Hans\|first4=V.\|last5=Riederer\|first5=B. M.\|last6=Krajewski\|first6=S.\|last7=Wiestler\|first7=O. D.\|last8=Reifenberger\|first8=G.\|date=2001-10\|title=Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells\|url=https://pubmed.ncbi.nlm.nih.gov/11589429\|journal=Journal of Neuropathology and Experimental Neurology\|volume=60\|issue=10\|pages=984–993\|doi=10.1093/jnen/60.10.984\|issn=0022-3069\|pmid=11589429}}</ref>, SOX10<ref>{{Cite journal\|last=Bannykh\|first=Sergei I.\|last2=Stolt\|first2=C. Claus\|last3=Kim\|first3=Jung\|last4=Perry\|first4=Arie\|last5=Wegner\|first5=Michael\|date=2006-01\|title=Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/16205963\|journal=Journal of Neuro-Oncology\|volume=76\|issue=2\|pages=115–127\|doi=10.1007/s11060-005-5533-x\|issn=0167-594X\|pmid=16205963}}</ref>		\|Positive (universal)\|\|Retained nuclear ATRX<ref name=":5">{{Cite journal\|last=Liu\|first=Xiao-Yang\|last2=Gerges\|first2=Noha\|last3=Korshunov\|first3=Andrey\|last4=Sabha\|first4=Nesrin\|last5=Khuong-Quang\|first5=Dong-Anh\|last6=Fontebasso\|first6=Adam M.\|last7=Fleming\|first7=Adam\|last8=Hadjadj\|first8=Djihad\|last9=Schwartzentruber\|first9=Jeremy\|date=2012-11\|title=Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations\|url=https://pubmed.ncbi.nlm.nih.gov/22886134\|journal=Acta Neuropathologica\|volume=124\|issue=5\|pages=615–625\|doi=10.1007/s00401-012-1031-3\|issn=1432-0533\|pmid=22886134}}</ref>, OLIG2<ref name=":21">{{Cite journal\|last=Ligon\|first=Keith L.\|last2=Alberta\|first2=John A.\|last3=Kho\|first3=Alvin T.\|last4=Weiss\|first4=Jennifer\|last5=Kwaan\|first5=Mary R.\|last6=Nutt\|first6=Catherine L.\|last7=Louis\|first7=David N.\|last8=Stiles\|first8=Charles D.\|last9=Rowitch\|first9=David H.\|date=2004-05\|title=The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/15198128\|journal=Journal of Neuropathology and Experimental Neurology\|volume=63\|issue=5\|pages=499–509\|doi=10.1093/jnen/63.5.499\|issn=0022-3069\|pmid=15198128}}</ref>, S100<ref name=":22">{{Cite journal\|last=Reifenberger\|first=G.\|last2=Szymas\|first2=J.\|last3=Wechsler\|first3=W.\|date=1987\|title=Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system\|url=https://pubmed.ncbi.nlm.nih.gov/3314309\|journal=Acta Neuropathologica\|volume=74\|issue=2\|pages=105–123\|doi=10.1007/BF00692841\|issn=0001-6322\|pmid=3314309}}</ref>, MAP2<ref name=":23">{{Cite journal\|last=Blümcke\|first=I.\|last2=Becker\|first2=A. J.\|last3=Normann\|first3=S.\|last4=Hans\|first4=V.\|last5=Riederer\|first5=B. M.\|last6=Krajewski\|first6=S.\|last7=Wiestler\|first7=O. D.\|last8=Reifenberger\|first8=G.\|date=2001-10\|title=Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells\|url=https://pubmed.ncbi.nlm.nih.gov/11589429\|journal=Journal of Neuropathology and Experimental Neurology\|volume=60\|issue=10\|pages=984–993\|doi=10.1093/jnen/60.10.984\|issn=0022-3069\|pmid=11589429}}</ref>, SOX10<ref name=":24">{{Cite journal\|last=Bannykh\|first=Sergei I.\|last2=Stolt\|first2=C. Claus\|last3=Kim\|first3=Jung\|last4=Perry\|first4=Arie\|last5=Wegner\|first5=Michael\|date=2006-01\|title=Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/16205963\|journal=Journal of Neuro-Oncology\|volume=76\|issue=2\|pages=115–127\|doi=10.1007/s11060-005-5533-x\|issn=0167-594X\|pmid=16205963}}</ref>
	\|-		\|-
	\|Positive (subset)\|\|Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref>{{Cite journal\|last=Capper\|first=David\|last2=Zentgraf\|first2=Hanswalter\|last3=Balss\|first3=Jörg\|last4=Hartmann\|first4=Christian\|last5=von Deimling\|first5=Andreas\|date=2009-11\|title=Monoclonal antibody specific for IDH1 R132H mutation\|url=https://pubmed.ncbi.nlm.nih.gov/19798509\|journal=Acta Neuropathologica\|volume=118\|issue=5\|pages=599–601\|doi=10.1007/s00401-009-0595-z\|issn=1432-0533\|pmid=19798509}}</ref>		\|Positive (subset)\|\|Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref name=":25">{{Cite journal\|last=Capper\|first=David\|last2=Zentgraf\|first2=Hanswalter\|last3=Balss\|first3=Jörg\|last4=Hartmann\|first4=Christian\|last5=von Deimling\|first5=Andreas\|date=2009-11\|title=Monoclonal antibody specific for IDH1 R132H mutation\|url=https://pubmed.ncbi.nlm.nih.gov/19798509\|journal=Acta Neuropathologica\|volume=118\|issue=5\|pages=599–601\|doi=10.1007/s00401-009-0595-z\|issn=1432-0533\|pmid=19798509}}</ref>

	Synaptophysin (cytoplasmic dot-like pattern<ref>{{Cite journal\|last=Perry\|first=Arie\|last2=Burton\|first2=Stephanie S.\|last3=Fuller\|first3=Gregory N.\|last4=Robinson\|first4=Christopher A.\|last5=Palmer\|first5=Cheryl A.\|last6=Resch\|first6=Lothar\|last7=Bigio\|first7=Eileen H.\|last8=Gujrati\|first8=Meena\|last9=Rosenblum\|first9=Marc K.\|date=2010-08\|title=Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall\|url=https://pubmed.ncbi.nlm.nih.gov/20464403\|journal=Acta Neuropathologica\|volume=120\|issue=2\|pages=237–252\|doi=10.1007/s00401-010-0695-9\|issn=1432-0533\|pmc=2892612\|pmid=20464403}}</ref>)		Synaptophysin (cytoplasmic dot-like pattern<ref name=":26">{{Cite journal\|last=Perry\|first=Arie\|last2=Burton\|first2=Stephanie S.\|last3=Fuller\|first3=Gregory N.\|last4=Robinson\|first4=Christopher A.\|last5=Palmer\|first5=Cheryl A.\|last6=Resch\|first6=Lothar\|last7=Bigio\|first7=Eileen H.\|last8=Gujrati\|first8=Meena\|last9=Rosenblum\|first9=Marc K.\|date=2010-08\|title=Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall\|url=https://pubmed.ncbi.nlm.nih.gov/20464403\|journal=Acta Neuropathologica\|volume=120\|issue=2\|pages=237–252\|doi=10.1007/s00401-010-0695-9\|issn=1432-0533\|pmc=2892612\|pmid=20464403}}</ref>)
	\|-		\|-
	\|Negative (universal)\|\|Lack diffuse p53<ref name=":5" />		\|Negative (universal)\|\|Lack diffuse p53<ref name=":5" />
Line 582:		Line 582:
	Oligodendrogliomas are most often low-grade, slow growing tumors		Oligodendrogliomas are most often low-grade, slow growing tumors

	* Tumors are frequently asymptomatic and are increasingly found incidentally on imaging for other indications<ref name=":20" />		*Tumors are frequently asymptomatic and are increasingly found incidentally on imaging for other indications<ref name=":20" />
	* Most commonly present with seizures<ref name=":4" />		*Most commonly present with seizures<ref name=":4" />
	* Can present with focal neurologic deficits or cognitive changes secondary to increased cranial pressure, especially in the high-grade setting<ref name=":4" />		*Can present with focal neurologic deficits or cognitive changes secondary to increased cranial pressure, especially in the high-grade setting<ref name=":4" />

	* Signs and symptoms - Seizures<ref name=":4" />; Headache; Signs of increased intracranial pressure (Focal neurologic deficits, Cognitive changes); Asymptomatic (increasingly an incidental finding on neuroimaging<ref name=":4" />)		*Signs and symptoms - Seizures<ref name=":4" />; Headache; Signs of increased intracranial pressure (Focal neurologic deficits, Cognitive changes); Asymptomatic (increasingly an incidental finding on neuroimaging<ref name=":4" />)
	* Laboratory findings - Not applicable		*Laboratory findings - Not applicable

	The <u>sites of involvement</u> of this disease are detailed below:		The <u>sites of involvement</u> of this disease are detailed below:

			* Approximately 60% of oligodendrogliomas occur within the frontal lobes with
			** 14-16% in the temporal lobe
			** 10-15% in the parietal lobe
			** 1-6% in the occipital lobe
			** Less commonly basal ganglia / cerebellum brainstem

			* Leptomeningeal spread and gliomatosis cerebri pattern can rarely occur
			* Rare spinal lesions have been reported but lack genotyping to confirm true oligodendroglioma
			* Extracranial metastasis exceedingly rare (CNS WHO grade 3)

	The <u>morphologic features</u> of this disease are detailed below:		The <u>morphologic features</u> of this disease are detailed below:

			* Classically consist of cells with round, monomorphous nuclei with stippled chromatin and perinuclear halos (artifactual fried-egg appearance)
			** Intervening delicate “chicken wire” vasculature
			** Can contain GFAP-positive minigemistocytes
			** Often contain microcalcifications, especially in low-grade tumors<ref name=":0" />

	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

	Positive (universal) -		Positive (universal) - Retained nuclear ATRX<ref name=":5" />, OLIG2<ref name=":21" />, S100<ref name=":22" />, MAP2<ref name=":23" />, SOX10<ref name=":24" />

	~~Positive (majority) -~~

	Positive (subset) -		Positive (subset) - Most positive for IDH1 p.R132H mutation (smaller subset lacking staining have non-canonical IDH mutation, <10%)<ref name=":25" />, Synaptophysin (cytoplasmic dot-like pattern<ref name=":26" />)

	Negative (universal) -		Negative (universal) - Lack diffuse p53<ref name=":5" />

	Negative (subset) -		Negative (subset) - N/A

	==Links==		==Links==

← Older revision		Revision as of 15:19, 27 March 2025
Line 559:		Line 559:
	This disease is <u>defined/characterized</u> as detailed below:		This disease is <u>defined/characterized</u> as detailed below:

			*Can be called anaplastic oligodendroglioma (historical; now known as oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3). It is discouraged to call this entity oligoastrocytoma (oligodendroglioma and astrocytoma are molecularly distinct entities. The diagnosis is reserved for rare cases where a dual genotype is identified, or where molecular testing could not be completed).
	*A molecularly defined diffusely infiltrating glioma with IDH1 or IDH2 mutation and codeletion of chromosome arms 1p and 19q<ref name=":0" /> .		*A molecularly defined diffusely infiltrating glioma with IDH1 or IDH2 mutation and codeletion of chromosome arms 1p and 19q<ref name=":0" /> .
	*Oligodendrogliomas are graded morphologically as either CNS WHO grade 2 or CNS WHO grade 3.		*Oligodendrogliomas are graded morphologically as either CNS WHO grade 2 or CNS WHO grade 3.
Line 591:		Line 592:
	The <u>sites of involvement</u> of this disease are detailed below:		The <u>sites of involvement</u> of this disease are detailed below:

	* Approximately 60% of oligodendrogliomas occur within the frontal lobes with		*Approximately 60% of oligodendrogliomas occur within the frontal lobes with
	** 14-16% in the temporal lobe		**14-16% in the temporal lobe
	** 10-15% in the parietal lobe		**10-15% in the parietal lobe
	** 1-6% in the occipital lobe		**1-6% in the occipital lobe
	** Less commonly basal ganglia / cerebellum brainstem		**Less commonly basal ganglia / cerebellum brainstem

	* Leptomeningeal spread and gliomatosis cerebri pattern can rarely occur		*Leptomeningeal spread and gliomatosis cerebri pattern can rarely occur
	* Rare spinal lesions have been reported but lack genotyping to confirm true oligodendroglioma		*Rare spinal lesions have been reported but lack genotyping to confirm true oligodendroglioma
	* Extracranial metastasis exceedingly rare (CNS WHO grade 3)		*Extracranial metastasis exceedingly rare (CNS WHO grade 3)

	The <u>morphologic features</u> of this disease are detailed below:		The <u>morphologic features</u> of this disease are detailed below:

	* Classically consist of cells with round, monomorphous nuclei with stippled chromatin and perinuclear halos (artifactual fried-egg appearance)		*Classically consist of cells with round, monomorphous nuclei with stippled chromatin and perinuclear halos (artifactual fried-egg appearance)
	** Intervening delicate “chicken wire” vasculature		**Intervening delicate “chicken wire” vasculature
	** Can contain GFAP-positive minigemistocytes		**Can contain GFAP-positive minigemistocytes
	** Often contain microcalcifications, especially in low-grade tumors<ref name=":0" />		**Often contain microcalcifications, especially in low-grade tumors<ref name=":0" />

	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below: